论文部分内容阅读
[目的]比较观察坎地沙坦西酯与硝苯地平治疗糖尿病肾病合并高血压的临床疗效。[方法]2009年12月～2010年12月,102例糖尿病肾病合并高血压患者随机分为坎地沙坦西酯组和硝苯地平组,每组51例,比较观察两组治疗前后血压和血尿素氮(BUN)、肌酐(Cr)水平变化。[结果]两组治疗后SBP、DBP明显降低,与治疗前比较差异均有统计学意义(P﹤0.05);两组治疗后SBP、DBP水平比较,差异无统计学意义(P﹥0.05)。坎地沙坦西酯组治疗后BUN及Cr水平明显降低,与治疗前比较差异有统计学意义(P﹤0.05);坎地沙坦西酯组治疗后BUN及Cr水平明显低于同期硝苯地平组(P﹤0.05),而硝苯地平组治疗前后BUN及Cr水平比较,差异无统计学意义(P﹥0.05)。[结论]坎地沙坦西酯与硝苯地平治疗糖尿病肾病合并高血压患者,均有明显的降压效果,但坎地沙坦西酯具有更好地保护肾脏作用,值得临床推广应用。
[Objective] To compare the clinical efficacy of candesartan cilexetil and nifedipine in the treatment of diabetic nephropathy complicated with hypertension. [Methods] From December 2009 to December 2010, 102 patients with diabetic nephropathy complicated with hypertension were randomly divided into candesartan cilexetil group and nifedipine group, with 51 cases in each group. The blood pressure, Blood urea nitrogen (BUN), creatinine (Cr) levels change. [Results] The SBP and DBP of the two groups were significantly lower after treatment than those before treatment (P <0.05). There was no significant difference in SBP and DBP after treatment between the two groups (P> 0.05). The levels of BUN and Cr in candesartan cilexetil group were significantly lower than those before treatment (P <0.05), while the levels of BUN and Cr in candesartan cilexetil group were significantly lower than those in the same period (P <0.05), while there was no significant difference in the level of BUN and Cr before and after treatment in nifedipine group (P> 0.05). [Conclusion] Both candesartan cilexetil and nifedipine have obvious antihypertensive efficacy in the treatment of diabetic nephropathy with hypertension, but candesartan cilexetil has better protection of the kidneys and is worthy of clinical application.